Lv21
120 积分 2022-07-23 加入
TL1A inhibition for inflammatory bowel disease treatment: From inflammation to fibrosis
2小时前
待确认
Understanding human mast cells: lesson from therapies for allergic and non-allergic diseases
1个月前
已完结
Mast cell silencing: A novel therapeutic approach for urticaria and other mast cell‐mediated diseases
1个月前
已完结
Preclinical discovery and initial clinical data of WVT078, a BCMA × CD3 bispecific antibody
1个月前
已完结
TL1A inhibition for inflammatory bowel disease treatment: From inflammation to fibrosis
2个月前
已完结
Stress-free single-cell transcriptomic profiling and functional genomics of murine eosinophils
3个月前
已完结
Avelumab in unresectable/metastatic, progressive, grade 2–3 neuroendocrine neoplasms (NENs): Combined results from NET-001 and NET-002 trials
4个月前
已完结
Assessment of Clinical Response Following Atezolizumab and Bevacizumab Treatment in Patients With Neuroendocrine Tumors
4个月前
已完结
Efficacy and Toxicity Analysis of Capecitabine and Temozolomide in Neuroendocrine Neoplasms
4个月前
已完结
Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study
4个月前
已完结
皖公网安备34019202002308
